B. Douglas Smith - Concepedia

Author

B. Douglas Smith

Sidney Kimmel Comprehensive Cancer Center ORCID

Also Known As

B D Smith, B Douglas Smith, B. D. Smith, B. Douglas Smith, B. Smith, B.D. Smith, B.Douglas Smith, Bruce D. Smith, Bruce Douglas Smith, Bruce Smith

308

Publications

11.2K

Citations

H-Index

105

Concepts

All Affiliations

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Johns Hopkins Medicine The University of Texas MD Anderson Cancer Center Sidney Kimmel Cancer Center

About

B. Douglas Smith is an author at Sidney Kimmel Comprehensive Cancer Center specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	2.6K
2	Health Sciences	7	7	324
3	Public Health	2	2	97
4	Engineering	1	1	57
5	Natural Sciences	1	1	44

B. Douglas Smith

118

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia B. Douglas Smith, Mark J. Levis, Miloslav Beran, Blood	2004	622
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Leukemia	2018	474
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse, Blood	2002	469
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease Leo Luznik, Javier Bolaños‐Meade, Marianna Zahurak, Blood	2010	396
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Mark J. Levis, Farhad Ravandi, Eunice S. Wang, Blood	2011	395
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Blood	2015	297
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology Jerald P. Radich, Michael W. Deininger, Camille N. Abboud, Journal of the National Comprehensive Cancer Network Hematological MalignancyChronic Myeloid LeukemiaMedicinePhiladelphia ChromosomeCancer Management	2018	281
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyChronic Myeloid LeukemiaMedicinePhiladelphia ChromosomeCancer Management	2020	264
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo Takashi Sato, Xiaochuan Yang, Steven Knapper, Blood	2011	254
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults Yvette L. Kasamon, Javier Bolaños‐Meade, Gabrielle T. Prince, Journal of Clinical Oncology	2015	237

Page 1